Abstract
Steroid-sensitive nephrotic syndrome often follows a relapsing course with a substantial number of patients requiring cytotoxic therapy with cyclophosphamide (CP). However, the long-term success of CP treatment is difficult to predict. We retrospectively evaluated 106 patients after CP to identify parameters associated with sustained remission. The overall rate of cumulative sustained remission was 24% after 10 years. No gender difference was found. Several factors were significantly correlated with the rate of sustained remission: age at CP therapy (remission 34% versus 9% in children older or younger than 5.5 years, P<0.01), frequently relapsing versus steroid-dependent status (54% versus 17%, P<0.05), leukopenia under CP treatment (44% in children with leukopenia versus 19% in children without leukopenia, P<0.05), and a cumulative dosage per body surface area (BSA) of more or less than 5,040 mg/m2 (45% versus 11%, P<0.01). In contrast, the cumulative dosage per kilogram body weight had no significant influence on long-term remission (23% in children with >168 mg/kg versus 26% in children with <168 mg/kg, P>0.05). The current concept of CP treatment of steroid-sensitive nephrotic syndrome is less effective in preschool children. CP therapy should be re-evaluated on a BSA-adjusted regimen.
Similar content being viewed by others
References
Brodehl J (1996) Management of nephrotic syndrome in children. Clin Immunother 5:175–192
Barratt TM, Soothill JF (1970) Controlled trial of cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood. Lancet II: 479–482
Latta K, Schnakenburg C von, Ehrich JHH (2001) A meta-analysis of cytotoxic treatment in frequently relapsing nephrotic syndrome in children. Pediatr Nephrol 16:271–282
International Study of Kidney Disease in Children (1978) Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. Kidney Int 13:159–165
Arbeitsgemeinschaft für Pädiatrische Nephrologie (1979) Alternate-day versus intermittent prednisone in frequently relapsing nephrotic syndrome. Lancet I: 401–403
Barratt TM, Osofsky SG, Bercowsky A, Soothill JF (1975) Cyclophosphamide treatment in steroid-sensitive nephrotic syndrome of childhood. Lancet I:55–58
McDonald J, Murphy AV, Arneil GC (1974) Long-term assessment of cyclophosphamide therapy for nephrosis in children. Lancet II:980–982
Konrad M, Mytilineos J, Ruder H, Opelz G, Schärer K (1997) HLA-DR 7 predicts the response to alkylating agents in steroid-sensitive nephrotic syndrome. Pediatr Nephrol 11:16–19
Arbeitsgemeinschaft für Pädiatrische Nephrologie (1982) Effect of cytotoxic drugs in frequent relapsing nephrotic syndrome with and without steroid dependency. N Engl J Med 306:451–454
Sladek NE, Priest J, Doeden D, Mirocha CJ, Pathre S, Krivit W (1980) Plasma half-life and urinary excretion of cyclophosphamide in children. Cancer Treat Rep 64:1061–1066
Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ, Pearson ADJ, Idle JR (1996) Cyclophosphamide pharmacokinetics in children. Br J Clin Pharmacol 41:13–19
Hoyer PF, Brodehl J, Ehrich JHH, Offner G (1991) Practical aspects in the use of cyclosporin in paediatric nephrology. Pediatr Nephrol 5:630–638
Weber LT, Shipkova M, Lamersdorf T, Niedmann PD, Wiesel M, Mandelbaum A, Zimmerhackl LB, Schutz E, Mehls O, Oellerich M, Armstrong VW, Tönshoff B (1998) Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol 9:1511–1520
Watson AR, Rance CP, Bain J (1985) Long term effects of cyclophosphamide on testicular function. BMJ 291:1457–1460
Acknowledgement
This study was supported by a grant from "Forschungsunterstützungskreis Kindernephrologie e.V." A part of this work was presented at the 33rd annual meeting of the European Society of Paediatric Nephrology, Prague, Czech Republic, 2–5 September 1999 and at the 12th congress of the International Pediatric Nephrology Association (IPNA), Seattle, USA, 1–5 September 2001 and published in abstract form (Pediatr Nephrol 1999 and 2001).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vester, U., Kranz, B., Zimmermann, S. et al. Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook. Pediatr Nephrol 18, 661–664 (2003). https://doi.org/10.1007/s00467-003-1170-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-003-1170-9